CHP-MAGE-A4 cancer vaccine study for refractory MAGE-A4-expressing cancer
Phase 1
- Conditions
- MAGE-A4-expressing refractory cancer patients (non origin-limited) or patients who refuse standard therapy
- Registration Number
- JPRN-UMIN000002153
- Lead Sponsor
- The Tazuke Kofukai Medical Research Institute
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 6
Inclusion Criteria
Not provided
Exclusion Criteria
1.HIV-positives 2.Double cancers 3.Autoimmune disease 4.History of serious hypersensitivity 5.Active CNS metastasis 6.Lasting less than four weeks from the previous chemotherapy, systemic corticosteroid, immuno-suppresive or stimulating agents, radiotherapy, or operation for primary tumors 7.Pregnant or lactating 8.Inappropriate for study entry judged by an attending physician
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Safety: maximum tolerated dose, dose-limiting toxicity, profiles of adverse events Efficacy: MAGE-A4-specific immune responses
- Secondary Outcome Measures
Name Time Method Efficacy: tumor responses, progression-free survival, overall survival, response duration time, and time to progression